Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
| 対象疾患 | Atrial Fibrillation, Stroke, Bleeding |
|---|---|
| 相 | 第3相 |
| スポンサー | Massachusetts General Hospital |
| ステータス | 完了 |
| 参加者数 | 100 名 |
| 介入（薬剤） | Rivaroxaban, Warfarin |
| 開始日 | 2019年4月30日 |
| 完了日 | 2023年10月1日 |
| 結果公開日 | 2026年5月19日 |
概要
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.
Postoperative Length of Stay
| Warfarin | 8 days |
|---|---|
| Rivaroxaban | 7 days |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomati — Insel Gruppe AG, University Hospital Bern
- Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
- Amplatzer Amulet China Post Market Study (PMS) — Abbott Medical Devices
- Diagnostic Accuracy of WEARable TECHnology Single-lead ECG in Detecting Cardiac Arrhythmia — Oxford University Hospitals NHS Trust
- Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With N — Intermountain Health Care, Inc.
- Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintai — Ottawa Heart Institute Research Corporation